Xencor XNCR Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Regeneron PharmaceuticalsREGN

$266.8M+13.8%

Janux TherapeuticsJANX

$20.99M-5.4%

AbCellera Biologics Inc.ABCL

$143.22M+119%

AnaptysBio, Inc.ANAB

$13.61K-99.9%

Immix Biopharma, Inc.IMMX

$1.04M-2.0%

Xenon PharmaceuticalsXENE

$6.42M-26.4%

FAQ

What is Xencor's operating lease liabilities (total)?

Xencor (XNCR) reported operating lease liabilities (total) of $65.21M in Q2 2026.

How has Xencor's operating lease liabilities (total) changed year-over-year?

Xencor's operating lease liabilities (total) decreased by 4.0% year-over-year, from $67.93M to $65.21M.

What is the long-term trend for Xencor's operating lease liabilities (total)?

Over 5 years (2020 to 2025), Xencor's operating lease liabilities (total) has grown at a 42.4% compound annual growth rate (CAGR), from $11.63M to $68M.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.